4//SEC Filing
Pierce Christopher 4
Accession 0001209191-21-055072
CIK 0001678660other
Filed
Sep 6, 8:00 PM ET
Accepted
Sep 7, 7:17 PM ET
Size
13.6 KB
Accession
0001209191-21-055072
Insider Transaction Report
Form 4
Pierce Christopher
EVP and Chief of Business Oper
Transactions
- Sale
Common Stock
2021-09-02$40.29/sh−3,343$134,697→ 17,407 total - Exercise/Conversion
Common Stock
2021-09-02$12.85/sh+17,000$218,450→ 20,750 total - Sale
Common Stock
2021-09-02$41.52/sh−6,727$279,289→ 10,680 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-09-02−17,000→ 207,796 totalExercise: $12.85Exp: 2030-09-01→ Common Stock (17,000 underlying) - Sale
Common Stock
2021-09-02$42.50/sh−6,930$294,507→ 3,750 total
Footnotes (5)
- [F1]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F5]The stock option vests as to 25% of the total shares monthly beginning on July 27, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
Documents
Issuer
Prelude Therapeutics Inc
CIK 0001678660
Entity typeother
Related Parties
1- filerCIK 0001824631
Filing Metadata
- Form type
- 4
- Filed
- Sep 6, 8:00 PM ET
- Accepted
- Sep 7, 7:17 PM ET
- Size
- 13.6 KB